Late-Breaking Trials & Science – TCT 2025 (San Francisco, Oct 25–28)
Late-Breaking Trials & Science – TCT 2025 (San Francisco, Oct 25–28)
Source: CRF Official Announcement (Newswise, Aug 27, 2025)
Note: Only study designs and titles have been announced.
👉 To know the final results, follow the TCT 2025 sessions (Oct 25–28, San Francisco) and subsequent publications in JACC and CRF outlets.
1. PCI & Stents
• Sirolimus-eluting balloon vs. DES for de novo lesions.
• Sirolimus balloon vs. repeat DES/balloon in ISR.
• Intravascular lithotripsy vs. cutting balloon (Short-CUT).
• Lithotripsy vs. super-high-pressure balloons (VICTORY).
2. Valvular Heart Disease
• PARTNER 3 trial – 7-year TAVR outcomes.
• PREVUE-VALVE – prevalence in older Americans.
• Tendyne TMVR in severe MAC (SUMMIT).
• Sapien M3 (ENCIRCLE trial) for mitral valve replacement.
3. ACS & Complex PCI
• Native artery vs. SVG PCI in prior CABG (PROCTOR).
• Low-dose tPA as adjunct in STEMI.
• iFR-guided vs. CMR-guided PCI in STEMI.
• MINOCA treatment (PROMISE).
• Supraflex Cruz vs. Xience in diabetics (TUXEDO-2).
4. Other Major Topics
• Pulmonary embolism (STORM-PE).
• LIFE-BTK resorbable scaffold.
• LAA closure: anticoagulation vs. DAPT.
• Evoque valve registry outcomes.
• TRILUMINATE pivotal – tricuspid TEER.
• Long-term PCI vs. CABG (NOBLE, 10 years).
• AI-enabled ECG in STEMI.
• Novel pVAD vs. IABP in high-risk PCI.
